4099
document
A comparative efficacy and safety study of clarithromycin , roxithromycin and erythromycin stearate in mild pneumonia . The efficacy and safety of clarithromycin , roxithromycin and erythromycin stearate in mild pneumonia were compared in an open randomized trial . Eighty-six male patients , doing their obligatory military service , ranging between 19 and 24 years of age ( mean 20 ) , were randomly treated : 29 with clarithromycin 500 mg 12-hourly , 30 with roxithromycin 150 mg 12-hourly , and 27 with erythromycin stearate 500 mg 6-hourly , each course being administered for 10 days . Seventy-eight patients were able to be evaluated for efficacy , 28 receiving clarithromycin , 28 roxithromycin , and 22 erythromycin stearate . There were no significant differences among the groups in terms of clinical success rates ( clinical cure or improvement : 89 % for clarithromycin , 82 % for roxithromycin , and 73 % for erythromycin stearate , p = 0.32 ) . However , we found that there were significant differences among the groups in terms of clinical cure rates ( 75 % for clarithromycin , 64 % for roxithromycin , and 41 % for erythromycin stearate , p = 0.04 ) . Adverse events , mostly gastrointestinal , caused discontinuation of treatment in 3.4 % of the patients in the clarithromycin group , in 6.6 % of the patients in the roxithromycin group , and in 18.5 % of the patients in the erythromycin stearate group . The results indicate that there were no statistically significant differences among the three treatment groups in terms of clinical success rates , but that clarithromycin and roxithromycin were better tolerated .
4100
Intervention_Pharmacological
clarithromycin
4101
Intervention_Pharmacological
roxithromycin
4102
Intervention_Pharmacological
erythromycin stearate
4103
Intervention_Pharmacological
clarithromycin
4104
Intervention_Pharmacological
roxithromycin
4105
Intervention_Pharmacological
erythromycin stearate
4106
Intervention_Pharmacological
clarithromycin 500 mg 12-hourly
4107
Intervention_Pharmacological
roxithromycin
4108
Intervention_Pharmacological
erythromycin
4109
Intervention_Pharmacological
clarithromycin
4110
Intervention_Pharmacological
roxithromycin
4111
Intervention_Pharmacological
erythromycin stearate
4112
Intervention_Pharmacological
clarithromycin
4113
Intervention_Pharmacological
roxithromycin
4114
Intervention_Pharmacological
erythromycin stearate
4115
Intervention_Pharmacological
clarithromycin
4116
Intervention_Pharmacological
roxithromycin
4117
Intervention_Pharmacological
erythromycin stearate
4118
Intervention_Pharmacological
clarithromycin
4119
Intervention_Pharmacological
roxithromycin
4120
Intervention_Pharmacological
erythromycin stearate
4121
Intervention_Pharmacological
clarithromycin
4122
Intervention_Pharmacological
roxithromycin
4123
Outcome_Other
efficacy and safety
4124
Outcome_Other
efficacy and safety
4125
Outcome_Other
efficacy
4126
Outcome_Physical
terms of clinical success rates
4127
Outcome_Physical
clinical cure rates
4128
Outcome_Adverse-effects
Adverse events , mostly gastrointestinal
4129
Outcome_Other
tolerated
4130
Participant_Condition
pneumonia
4131
Participant_Sample-size
Eighty-six
4132
Participant_Sex
male
4133
Participant_Age
19 and 24 years
4134
Participant_Sample-size
Seventy-eight